We are live on ! Find out more
MREO

Mereo BioPharma
MREO

71 hedge funds and large institutions have $283M invested in Mereo BioPharma in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

44% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 16

22% more call options, than puts

Call options by funds: $547K | Put options by funds: $447K

8% more funds holding

Funds holding: 66 → 71 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.15% less ownership

Funds ownership: 13.69% → 13.55% (-0.15%)

7% less capital invested

Capital invested by funds: $305M → $283M (-$21.4M)

Holders
71
Holders Change
+5
Holders Change %
+7.58%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
23
Reduced
16
Closed
10
Calls
$547K
Puts
$447K
Net Calls
+$100K
Net Calls Change
-$237K

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$9.21M
2
SCM
Suvretta Capital Management
New York
+$7.66M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6.14M
4
TLP
Tri Locum Partners
New York
+$4.21M
5
Holocene Advisors
Holocene Advisors
New York
+$2.75M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$14.4M
2
BBA
Baker Bros. Advisors
New York
-$14.3M
3
SFM
Sphera Funds Management
Israel
-$4.42M
4
Millennium Management
Millennium Management
New York
-$3.1M
5
ECM
Endurant Capital Management
California
-$1.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$54.7M – – –
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$32M +$6.14M +1,830,689 +22%
SCM
3
Suvretta Capital Management
New York
$27.4M +$7.66M +2,283,800 +36%
BC
4
Boxer Capital
California
$19.7M – – –
RCMNY
5
Rubric Capital Management (New York)
New York
$17.9M +$9.21M +2,745,747 +94%
RSCM
6
Rock Springs Capital Management
Maryland
$14.4M +$161K +47,900 +1%
VC
7
Vivo Capital
California
$13.4M – – –
HA
8
HHLR Advisors
Cayman Islands
$9.43M – – –
Citadel Advisors
9
Citadel Advisors
Florida
$9.36M +$1.73M +516,810 +21%
BBA
10
Baker Bros. Advisors
New York
$7.8M -$14.3M -4,260,549 -63%
CC
11
Commodore Capital
New York
$6.53M +$36.8K +10,972 +0.5%
Holocene Advisors
12
Holocene Advisors
New York
$6.18M +$2.75M +819,750 +73%
Alkeon Capital Management
13
Alkeon Capital Management
New York
$6.14M – – –
PA
14
Perceptive Advisors
New York
$5.38M -$14.4M -4,303,932 -72%
Millennium Management
15
Millennium Management
New York
$5.28M -$3.1M -925,417 -36%
ACM
16
Asymmetry Capital Management
California
$5.13M +$1.86M +555,064 +52%
AG
17
Artal Group
Luxembourg
$4.75M – – –
SSA
18
Schonfeld Strategic Advisors
New York
$4.2M +$174K +52,000 +4%
TLP
19
Tri Locum Partners
New York
$3.97M +$4.21M +1,253,729 New
ACM
20
Altium Capital Management
New York
$3.96M – – –
DCM
21
DAFNA Capital Management
California
$3.57M -$413K -123,035 -10%
TCM
22
Tekla Capital Management
Massachusetts
$3.31M +$159K +47,500 +5%
MIM
23
Monashee Investment Management
Massachusetts
$2.54M -$671K -200,000 -20%
ECM
24
Endurant Capital Management
California
$2.4M -$1.96M -582,920 -44%
AAA
25
Affinity Asset Advisors
New York
$2.06M -$839K -250,000 -28%
1
2 3 4

MREO Hedge Fund Activity: Q2 2021 in Review

71 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2021, worth a combined $283M — down 7% from $305M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new MREO positions and 10 closed out — a net gain of 5 holders — while 23 added to existing stakes and 16 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $9.21M. The largest seller was Perceptive Advisors, cutting an estimated $14.4M.

  • 71 institutional investors held Mereo BioPharma (MREO) as of Q2 2021, up from 66 in Q1 2021.
  • Funds reported $283M of Mereo BioPharma stock for Q2 2021, down 7% quarter-over-quarter.
  • 15 funds opened new Mereo BioPharma positions in Q2 2021 and 10 closed out, a net change of +5 holders.
  • The largest Mereo BioPharma buyer in Q2 2021 was Rubric Capital Management (New York), an estimated $9.21M added.
  • The largest Mereo BioPharma seller in Q2 2021 was Perceptive Advisors, an estimated $14.4M sold.

Based on aggregated 13F filings for Q2 2021.